The revision of the pharmaceutical legislation - it is time to act for nuclear medicine in Europe

Eur J Nucl Med Mol Imaging. 2023 Dec;51(1):20-24. doi: 10.1007/s00259-023-06472-1.

Marianne Patt¹, Clemens Decristoforo², Amélie de Martini³, Michel Koole⁴, Wim J G Oyen^{5

6

7}, Oliver C Kiss⁸

¹ Section Radiopharmacy, Department of Nuclear Medicine, University Hospital Augsburg, Augsburg, Germany.
² Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria.
³ European Association of Nuclear Medicine, Vienna, Austria.
⁴ Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Louvain, Belgium.
⁵ Department of Biomedical Sciences and Humanitas Clinical and Research Centre, Department of Nuclear Medicine, Humanitas University, Milan, Italy.
⁶ Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, The Netherlands.
⁷ Department of Medical Imaging, Nuclear Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands.
⁸ Department of Targetry, Target Chemistry and Radiopharmacy, Institute for Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany. o.kiss@hzdr.de.

No abstract available

Publication types